Wed, Nov 5, 2014, 8:30AM EST - US Markets open i

Wed, Nov 5, 2014, 8:30AM EST - US Markets open in 60 mins


ScripsAmerica, Inc.

Small Cap Traders Provides Brief Report on ScripsAmerica

.

PR Newswire
Small Cap Traders
1 hour ago



NEW YORK, Nov. 5, 2014 /PRNewswire/ -- Analyst Brief by Small Cap Traders. -- ScripsAmerica, Inc. (SCRC) is a supplier of prescription, OTC and nutraceutical drugs incepted in 2008 in the US. The firm provides pharmaceutical products to a wide range of end users including retail pharmacies, hospitals, long-term care facilities, government, and home care agencies. After experiencing a significant drop in profit margins in 2013, the firm restructured and has been experiencing a tremendous growth in both revenue and profit since the beginning of 2014. Q2 2014, ScripsAmerica reported $3,700,721 in total net revenue in compared to $91,628 reported during the same period in 2013, marking an increase of $3,609,093 in quarterly revenue. Also, profit margin in Q2 is 87%, in compare with a loss in 2013, signaling a positive trend for the firm. This growth in margin contributed to its management of the specialty pharmacy business which generated significant sales in the first six months of 2014.





On October 28th, 2014, ScripsAmerica confirmed its presence at See ThruEquity Microcap Investor Conference on November 12th in New York City. This gives ScripsAmerica a lucrative opportunity to access more funding from the investment community.

Since the beginning of the year, ScripsAmerica has continuously formed collaborative agreements with multiple players in the industry through acquisitions and partnerships. These firms include United Apothecapy, RapiMed Manufacturer, and Jungle Jim. As for the agreement with Jungle Jim, not only does it provide ScripsAmerica additional revenue base but also access to process prescriptions in 12 new states across the country. Going forward, with the increase in the revenue and customer base, the company should focus on ensuring strict control on its inventory, while achieving minimum turnaround time.

For a more detailed research with analyst comments and recommendation on ScripsAmerica, please follow the link. There is no cost obligation required to view analyst brief:

http://bit.ly/-SCRC-AnalystBrief